Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2Phase 3 1

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 2Recurrence 1Neoplasms 1Neoplasm Metastasis 1

Interventions

Carboplatin 551Pemetrexed 404Cisplatin 401Paclitaxel 273Docetaxel 255Gemcitabine 218pembrolizumab 191Bevacizumab 190Erlotinib Hydrochloride 184Radiotherapy 181Etoposide 147durvalumab 140Nivolumab 134Drug Therapy 127osimertinib 107atezolizumab 92Gefitinib 74Radiosurgery 72anlotinib 69Vinorelbine 68tislelizumab 52Irinotecan 51Ipilimumab 50130-nm albumin-bound paclitaxel 50Taxes 48Surgical Procedures, Operative 46Cetuximab 46sintilimab 45Albumin-Bound Paclitaxel 45apatinib 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × rociletinib × Thoracic × Clear all
NCT02147990 2020-08-12

NSCLC

Clovis Oncology, Inc.

Phase 2 Terminated
318 enrolled 29 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms, Recurrence

NCT02705339 2016-05-17

Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC)

Washington University School of Medicine

Phase 2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡